Loading organizations...
§ Private Profile · 160 Varick St 3rd Floor, New York, NY 10013, USA
AI technology company developing AI platforms for pharmaceutical and biotech sectors, focused on transforming drug development.
Intelligencia AI has raised $16.0M across 2 funding rounds.
Key people at Intelligencia AI.
Intelligencia AI was founded by Vangelis Vergetis (Co-founder & CEO).
Intelligencia AI has raised $16.0M in total across 2 funding rounds.
Intelligencia AI develops artificial intelligence technology designed to transform drug development by addressing lengthy timelines, high costs, and suboptimal return on investment within the pharmaceutical sector. The company leverages proprietary data, deep biomedical expertise, and advanced AI models to solve major challenges, offering its AI platform to major pharmaceutical and biotech clients. Intelligencia AI has successfully raised a total of $15.5 million in funding, which includes a $12 million Series A round. The firm has garnered recognition, notably being named by Forbes as one of its Top AI Companies to Watch in 2021 and among America's top 50 most promising AI companies. Its leadership team includes CEO Dimitrios Skaltsas, Vangelis Vergetis, and Chief AI Officer Gerry Liaropoulos. Intelligencia AI was founded in 2017 by Dimitrios Skaltsas and Vangelis Vergetis.
Intelligencia AI has raised $16.0M across 2 funding rounds. Most recently, it raised $12.0M Series A in August 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 10, 2021 | $12M Series A | Danchen Zhao | BIG PI Ventures, Synetro Group, Pratap Khedkar | Announced |
| Nov 1, 2018 | $4M Seed | — | Smartstart Fund | Announced |
Key people at Intelligencia AI.
Intelligencia AI was founded by Vangelis Vergetis (Co-founder & CEO).
Intelligencia AI has raised $16.0M in total across 2 funding rounds.
Intelligencia AI's investors include Danchen Zhao, Big Pi Ventures, Synetro Group, Pratap Khedkar, SmartStart Fund.
Intelligencia AI is an AI-driven technology company that builds SaaS-based solutions to de-risk drug development for pharmaceutical and biotechnology firms. Its core products, such as Portfolio Optimizer, Asset Optimizer, and BD&L Navigator, predict clinical trial outcomes, assess probability of technical and regulatory success (PTRS), optimize portfolios, and identify external assets, serving large global pharma companies and mid-sized biotechs.[1][2][3] By leveraging curated clinical data, proprietary ontologies, and patented AI models, the company tackles high drug development costs, long timelines, and low ROI through unbiased, transparent risk assessments with over 80% prospective accuracy.[2][3][4][6] Founded around 2017-2018 and headquartered in New York with offices in Athens, Greece, it employs 110 people, reported $23.1M revenue, raised $12M in Series A funding, and ranked No. 1819 on the 2024 Inc. 5000 with 287% three-year growth.[2][3][4][5]
Intelligencia AI was founded in 2017 (with some sources citing 2018) by Dimitrios Skaltsas, its CEO and co-founder, who brought over a decade of healthcare and life sciences leadership experience before launching the venture.[1][2][4] Emerging from the founders' recognition of inefficiencies in the $1.5 trillion pharmaceutical industry—particularly risky, costly drug development—the company assembled a global, interdisciplinary team of data scientists, clinical experts, and biomedical researchers.[4] Early milestones include a 2021 Series A funding round, a strategic partnership with ZS (a global services firm), and Forbes recognition as a Top AI Company to Watch; in 2024, it secured a U.S. patent for ML techniques predicting FDA approval likelihood and earned Inc. 5000 honors.[3][4]
Intelligencia AI rides the AI-for-biopharma wave, capitalizing on surging demand for data-driven tools amid rising drug development failures (90%+ attrition rates) and costs exceeding $2B per asset. Its timing aligns with post-2020 AI advancements in healthcare, regulatory nods to AI (e.g., FDA pilots), and biopharma's digital transformation push, fueled by investor interest in de-risking startups.[2][3][4] Market forces like personalized medicine, real-world evidence needs, and M&A activity favor its external innovation tools, while its patented tech sets it apart from competitors like BioMedTracker.[1] The company influences the ecosystem by accelerating therapies to patients, standardizing risk assessment, and enabling bolder portfolio decisions for 110+ employees' global operations.[2][4][6]
Intelligencia AI's momentum—Inc. 5000 ranking, patent wins, and pharma partnerships—positions it for expansion into more therapeutic areas and adjacent services like real-world evidence analytics. Trends like multimodal AI, federated learning for data privacy, and AI regulatory harmonization will amplify its edge, potentially scaling revenue beyond $23M via enterprise deals. As biopharma chases efficiency in a high-interest-rate world, its unbiased PTRS tools could evolve influence from niche advisor to industry standard, bringing life-changing drugs faster while sustaining 200%+ growth.[3][5][6] This de-risking pioneer exemplifies how AI transforms pharma's high-stakes gamble into calculated precision.
